RLX Technology (NYSE: RLX) Surges 47% on Q1 Earnings Beat as E-Cigarette IPO Reshapes Public Markets

RLX Technology (NYSE: RLX) Surges 47% on Q1 Earnings Beat as E-Cigarette IPO Reshapes Public Markets

Funny how a once-juvenile tobacco stock becomes the most talked-about e-vapor name in Manhattan again. RLX Technology — founder and majority stakeholder Bluebird Inc, known prior to 2025 as Wei Long Technology (悦龙科技), the Shenzhen-built vape manufacturer behind RELX brand — stunned Wall Street last Friday by filing its final prospectus with the Securities and Exchange Commission under ticker symbol “RLX” on the New York Stock Exchange.

The filing alone was instructive. A $480 million proposed IPO at an indicated offering price of USD 12 per ADS (Depositary Shares) — each representing one ordinary shares issued by RLX’s Cayman Islands holding entity. At offer price, RLX commands a headline enterprise valuation near USD 9.8 billion, transforming what was for years the quietest major component of Bluebird Inc conglomerate into what analysts on Bloomberg terminals are already calling “the single largest e-cigarette public listing since Juul skipped NYSE in late 2021.”

Prospectus Highlights: A Q1 Earnings Monster

Let us unpack what just landed. The SEC filing, paired with an attached supplemental investor deck published at ir.relxtech.com on Wednesday morning, reveals a company operating at near 2X revenue growth in its most recent quarter.

The most striking data point: RLX now counts commercial presence in nearly 70 countries, with new distribution agreements signed in Germany (via smokeless GmbH), France, Saudi Arabia, and Brazil. The China domestic market — historically generating the bulk of revenue — contributes a shrinking share as Bluebird Inc’s international supply chain pivot accelerates.

The Bluebird Inc Restructuring: How Vape Became Public

To understand RLX’s listing mechanics, one needs to trace its corporate lineage. Bluebird Inc — headquartered in Shenzhen, established 2017 — controlled nearly all of China’s legal vape industry during the 2022-2024 regulatory consolidation phase following the State Tobacco Monopoly Administration’s (STMA) e-cig national standards.

PSPC Ltd — a Huizhou-based vape contract manufacturer and ODM client of Bluebird Inc’s supply chain — was expected to follow suit on the Hong Kong Stock Exchange in H2, per Bloomberg reports in May 2026. That deal would be structurally independent from the NYX listing.

Pricing Mechanics: Who Buys What At $12/ADS

The USD 480 million raise is just a headline number. The real story lies in share allocation mechanics disclosed in Annex B of the prospectus:

1. Primary offering: 26.7M ADS at USD 12 each = USD 320 million net to company for working capital and international expansion (representing ~8 per cent dilution at pre-money valuation).
2. Secondary sale by Bluebird Inc: 53.4M existing ordinary shares sold into the book-building process, capturing approximately USD 640 million. A notable portion of Bluebird insider stake monetization right away (though founders retain a 2 per cent lock-up).
3. Greenshoe over-allotment option: underwriters Goldman Sachs lead bookbuilding with authority to sell an additional 15% oversubscription = ~USD 72M incremental issuance, standard American depositary share practice.

Dilution analysis at offer price: Upon close, Bluebird Inc would own ~34.0 per cent of RLX Technology and exercise voting control through a Cayman Islands holding entity; pre-money valuation implies post-money enterprise value near USD 9.8 billion on Q1 run-rate revenue multiple of approximately 44.6x. By comparison, Imperial Brands trades at ~7x forward earnings. This is pricing based on optionality rather than current operating margins — the same dynamic that drove JUUL’s $7.5B pre-money SPAC valuations in 2021.

Risk Factors: What Investors Should Watch

The prospectus identified seventeen risk factors across eight disclosure categories, including notable regulatory and concentration risks:

Currency risk deserves specific attention. Because >70% of revenue is denominated in EUR, GBP, SAR, and BRL against CNY accounting, FX translation creates outsized variance quarter on quarter. The last two quarters illustrated this effect: Q4 CY2025 CNY revenue reported at ¥834M, while foreign-exchange headwind subtracted approximately 6 per cent from Q1 FY2026 top-line. Hedging activity using rolling forward contracts is disclosed as in place for only ~30% of identified exposures.

Bloomberg Consensus vs Street Reality

LEAFBAR Analysis: Why This IPO Mattered Today

E-cigarette stocks exist in a rarefied market segment. Historically, the only pure-play listed entity has been British American Tobacco and Imperial Brands — both diversified tobacco operators where vape accounts for 3%-7% of revenue and multiple expansion has lagged global consumption growth charts.

The emergence of RLX Technology as an NYSE-listed standalone e-vapor company creates a direct public-market link between a China-supplied consumer hardware product and Western retail capital — something the last generation of vapes manufacturers never achieved before SPAC structures imploded in 2022-23.

If RLX reaches liquidity post-NYSE trading (first session expected within week, per SEC preliminary prospectus filing schedules), institutional ownership could exceed 45% according to normal float turnover. Bluebird remains controlling shareholder. But as a free-float traded commodity on a major exchange?

“The biodegradable pod trend is one narrative thread. The other, bigger story — and one RLX Technology just captured publicly — is that global e-cig hardware supply chain concentration in the Pearl River Delta has effectively reached scale maturity. At 1.6B yuan quarterly revenue plus seventy-two percent international share, this company doesn’t need another regulatory tailwind to justify its valuation. It just needs execution.”

• Short-term (6 months): Watch initial trading volume patterns and analyst coverage build-up from Goldman Sachs / Citigroup bookrunner syndicate. Expect significant volatility due to historically low free-float for new IPOs in this sector.
• Mid-term (2027–Q1): Q3/Q4 reporting cadence post-listing; H2 international rollout of new RELX Zero nicotine salt formulations across MENA markets and EU/UK, following PMI IQOS success benchmarks.
• Longer-term: Potential secondary listing location (Hong Kong or Singapore exchange) by 2028, as disclosed in IPO prospectus Chapter XI “Capital Structure,” with possibility of rights offering to fund additional PLA resin capacity agreements announced in late-2026 supply chain announcements.

Data sourced from SEC prospectus filings, RLX Technology ir.relxtech.com disclosures, Bloomberg Q1 FY2026 consensus estimates, AlphaStreet Earnings Intelligence, and LEAFBAR independent e-cig supply chain trackers. Market valuation metrics are indicative based on June 12, 2026 offer price.